OPK · Opko Health, Inc.
$1.38
-0.02 (-1.43%)
At close · Aug 14
Market Cap
$1.03B
Shares
746.33M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$606.88M
-14.9%
FY2025
Net Income
-$225.68M
-324%
FY2025
Gross Margin
33.93%
+3.3pp
FY2025
Operating Margin
-19.35%
+2pp
FY2025
Diluted EPS
-$0.30
-275%
FY2025
Operating Cash Flow
-$178.54M
+2.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $587.9M | $606.88M | $713.14M | $863.5M | $1B | $1.77B | $1.44B | $901.94M | $990.27M | $966.01M | $1.12B | $491.74M | $91.13M | $96.53M | $47.04M | $27.98M | $28.49M | $4.42M | |
| $348.21M | $400.94M | $494.63M | $545.37M | $715.98M | — | — | — | — | $61.18M | $564.1M | $193.31M | $9.37M | $10.42M | $27.88M | $17.24M | $13.5M | $2.88M | |
| $239.69M | $205.94M | $218.51M | $318.13M | $288.22M | — | — | — | — | — | — | — | — | — | $19.17M | $10.74M | $15M | $1.54M | |
| — | 33.93% | 30.64% | 36.84% | 28.7% | — | — | — | — | — | — | — | — | — | 40.74% | 38.37% | 52.64% | 34.9% | |
| $125.22M | $124.03M | $105.21M | $89.59M | $73.89M | $76.85M | $75.32M | $117.87M | $125.59M | $126.44M | $113.87M | $99.49M | $83.57M | $53.9M | $19.52M | $11.35M | $5.95M | $10.84M | |
| $205.85M | $223M | $304.22M | $300.56M | $372.67M | $468.86M | $355.57M | $343.31M | $358.35M | $414.63M | $407.33M | $196.58M | $57.94M | $55.32M | $27.8M | $19.17M | $18.13M | $10.37M | |
| $76.52M | $77.89M | $82.63M | $86.03M | $87.78M | $50.28M | $56.39M | $64.78M | $67.93M | $71.48M | $64.41M | $27.98M | $10.92M | $11.13M | $8.34M | $3.4M | $2.1M | — | |
| $89.72M | $91.63M | $98.18M | $105.3M | $108.66M | $78.72M | $85.36M | $93.81M | $97.34M | $102.09M | $96.58M | $42.25M | $14.93M | $15.22M | $10.16M | $3.83M | $2.21M | $564K | |
| $2.6M | — | — | — | — | — | — | — | — | — | — | — | — | — | $785K | — | — | — | |
| $724.29M | — | — | $1.02B | $1.23B | $1.76B | $1.38B | $1.18B | $1.16B | $1.24B | $1.21B | $590.22M | $236.94M | $176.16M | $84.31M | $51.17M | $26.14M | $23.69M | |
| $636.15M | $724.29M | $865.21M | $1.02B | $1.23B | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$48.25M | -$117.41M | -$152.07M | -$157.02M | -$226.25M | $18.75M | $57.71M | -$274.05M | -$171.2M | -$276.44M | -$96.55M | -$98.48M | -$145.82M | -$79.63M | -$37.27M | -$23.19M | -$11.14M | -$22.15M | |
| — | -19.35% | -21.32% | -18.18% | -22.53% | 1.06% | 4.02% | -30.38% | -17.29% | -28.62% | -8.64% | -20.03% | -160.02% | -82.49% | -79.22% | -82.88% | -39.08% | -501.29% | |
| $41.47M | -$25.78M | -$53.89M | -$51.72M | -$117.6M | $97.47M | $143.08M | -$180.25M | -$73.85M | -$174.35M | $25K | -$56.23M | -$130.89M | -$64.42M | -$27.11M | -$19.36M | -$8.93M | -$21.58M | |
| -$63.47M | $0 | $47.47M | $13.51M | $12.06M | $18.88M | — | — | — | — | — | — | — | — | — | $1.01M | $1.22M | $1.76M | |
| $13.07M | $14.81M | $8.43M | $3.98M | $1.98M | $28K | — | — | — | — | — | — | — | — | — | $288K | $24K | $24K | |
| -$31.58M | -$123.96M | $141.7M | -$27.3M | -$165.27M | -$32.78M | -$9.03M | -$30.91M | -$6.07M | $4.52M | -$271K | -$39.52M | -$25.21M | -$24.59M | $165K | -$1.04M | -$844K | -$1.92M | |
| -$22K | -$29K | -$18K | -$107K | -$383K | -$629K | -$480K | -$2.9M | -$14.5M | -$14.47M | -$7.65M | -$7.11M | -$3.59M | -$11.46M | -$2.06M | -$1.59M | — | — | |
| -$15K | — | — | -$107K | -$383K | -$629K | -$480K | -$2.9M | -$14.5M | -$14.47M | -$7.65M | -$7.11M | -$3.59M | -$11.46M | -$2.06M | -$1.59M | -$714K | -$353K | |
| -$79.83M | -$241.36M | -$10.36M | -$184.32M | -$391.52M | -$14.03M | $48.68M | -$304.97M | -$177.27M | -$271.92M | -$96.82M | -$138M | -$171.03M | -$104.22M | -$37.1M | -$24.23M | -$11.98M | -$24.06M | |
| -$6.96M | -$15.71M | $42.84M | $4.44M | -$63.5M | $15.49M | $17.62M | $7.06M | -$38.73M | $18.86M | -$56.12M | -$113.68M | $24K | $1.67M | -$9.63M | -$19.36M | -$18K | -$25K | |
| -$72.89M | -$225.68M | -$53.22M | -$188.86M | -$328.41M | -$30.14M | $30.59M | -$314.93M | -$153.04M | -$305.25M | -$48.36M | -$30.03M | -$171.67M | -$114.41M | -$29.05M | -$1.28M | -$18.93M | -$30.11M | |
| — | -37.19% | -7.46% | -21.87% | -32.7% | -1.7% | 2.13% | -34.92% | -15.45% | -31.6% | -4.33% | -6.11% | -188.39% | -118.52% | -61.75% | -4.59% | -66.42% | -681.6% | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | -$1.4M | -$2.97M | -$2.94M | -$492K | $0 | — | — | |
| — | — | — | — | — | — | — | — | — | -$308.87M | -$25.08M | -$30.03M | -$171.67M | -$114.83M | -$31.29M | -$3.66M | -$21.55M | -$34.83M | |
| -$76.55M | -$190.57M | -$71.32M | -$183.57M | -$341.23M | -$56.41M | $48.43M | -$316.86M | -$172.64M | -$278.77M | — | -$40.17M | -$187.48M | -$118.35M | -$22.6M | -$5.68M | -$19.94M | — | |
| USD/shares | — | -$0.30 | -$0.08 | -$0.25 | -$0.46 | -$0.05 | $0.05 | -$0.53 | -$0.27 | -$0.55 | -$0.09 | -$0.11 | — | — | — | -$0.01 | -$0.08 | -$0.15 |
| USD/shares | — | -$0.30 | -$0.08 | -$0.25 | -$0.46 | -$0.05 | $0.05 | -$0.53 | -$0.27 | -$0.55 | -$0.10 | -$0.11 | — | — | — | — | — | — |
| shares | — | 751.13M | 694.02M | 751.77M | 719.06M | 648.08M | 640.66M | 595.45M | 563.14M | 559.16M | 550.85M | 488.07M | 422.01M | 355.1M | 295.75M | 280.67M | — | — |
| shares | — | 751.13M | 694.02M | 751.77M | 719.06M | 648.08M | 640.66M | 595.45M | 563.14M | 559.16M | 555.61M | 488.07M | 422.01M | 355.1M | 295.75M | 280.67M | 255.1M | 233.19M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $145.1M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.24×
Peer median 3.03×
EV/EBIT
—
Peer median 91.57×
P/E (TTM)
—
Peer median 29.46×
Peer medians compare against the 19 similar-size Diagnostics & Research companies (of 49 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $370,275,000 | $480,667,000 | $515,275,000 | $755,630,000 | $1,607,106,000 | $1,278,482,000 | $716,434,000 | $813,248,000 |
| Pharmaceutical | $236,604,000 | $232,475,000 | $348,220,000 | $248,566,000 | $167,612,000 | $156,931,000 | $184,705,000 | $177,018,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $436,061,000 | $546,300,000 | $597,822,000 | $783,207,000 | $1,640,354,000 | $1,317,766,000 | $751,099,000 | $837,509,000 |
| Chile | $62,377,000 | $65,049,000 | $68,491,000 | $62,044,000 | $63,798,000 | $44,153,000 | $33,642,000 | $41,216,000 |
| Ireland | $51,401,000 | $48,397,000 | $141,465,000 | $117,214,000 | $32,809,000 | $43,920,000 | $81,170,000 | $78,102,000 |
| Spain | $26,725,000 | $24,634,000 | $23,517,000 | $22,477,000 | $22,682,000 | $16,932,000 | $18,747,000 | $18,195,000 |
| Mexico | $25,520,000 | $23,867,000 | $20,216,000 | $14,546,000 | $11,005,000 | $7,865,000 | $8,032,000 | $5,598,000 |
| Other Countries | $4,273,000 | $3,123,000 | $2,246,000 | $863,000 | $507,000 | $526,000 | $476,000 | $167,000 |
| Israel | $522,000 | $1,772,000 | $9,738,000 | $3,845,000 | $3,563,000 | $4,251,000 | $8,769,000 | $9,479,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Service | $370,275,000 | $480,667,000 | $515,275,000 | $755,630,000 | $1,607,106,000 | $1,262,242,000 | $716,434,000 | $813,248,000 |
| Product | $156,924,000 | $155,111,000 | $167,557,000 | $142,845,000 | $141,770,000 | $119,952,000 | $112,184,000 | $107,112,000 |
| Transfer of Intellectual Property and Other | $79,680,000 | $77,364,000 | $180,663,000 | $105,721,000 | $25,842,000 | $53,219,000 | $73,317,000 | $69,906,000 |
| Rayaldee | $59,389,000 | $69,299,000 | $67,547,000 | $59,557,000 | $64,301,000 | $88,187,000 | $73,965,000 | $36,715,000 |
| Client Payers | — | — | — | $316,309,000 | $843,405,000 | $637,645,000 | $158,527,000 | $148,070,000 |
| Government Payers | — | — | — | $97,191,000 | $222,242,000 | $90,288,000 | $115,711,000 | $150,851,000 |
| Health Insurers | — | — | — | $326,144,000 | $520,244,000 | $483,643,000 | $421,386,000 | $492,995,000 |
| Patients | — | — | — | $15,986,000 | $21,215,000 | $50,666,000 | $20,810,000 | $21,332,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $21,259,000 | -$24,125,000 | -$155,596,000 | -$173,652,000 | $98,067,000 | $138,922,000 | -$123,359,000 | -$44,942,000 |
| Pharmaceutical | -$98,342,000 | -$86,795,000 | $41,184,000 | -$12,961,000 | -$19,051,000 | -$43,519,000 | -$109,062,000 | -$82,641,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | 5.7% | -5% | -30.2% | -23% | 6.1% | 10.9% | -17.2% | -5.5% |
| Pharmaceutical | -41.6% | -37.3% | 11.8% | -5.2% | -11.4% | -27.7% | -59% | -46.7% |
Key facts
CIK
944809
CUSIP
68375N103
13F (30d)
205 filings
204 filers
Visit website
Investor relations